Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Citius Pharmaceuticals, Inc. (CTXR) had Normalized Income after Taxes of $-9.20M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-8.79M |
|
-- |
|
-- |
|
$8.79M |
|
$-8.79M |
|
$-0.15M |
|
$-8.94M |
|
$-8.94M |
|
$-9.20M |
|
$-9.20M |
|
$-9.20M |
|
|
Normalized Income after Taxes |
$-9.20M |
$-8.79M |
|
$-8.75M |
|
11.01M |
|
11.01M |
|
$-0.80 |
|
$-0.80 |
|
| Balance Sheet Financials | |
$24.61M |
|
-- |
|
$103.07M |
|
$127.68M |
|
$51.84M |
|
-- |
|
$8.27M |
|
$60.12M |
|
$67.56M |
|
$58.21M |
|
$67.56M |
|
14.47M |
|
| Cash Flow Statement Financials | |
$-14.67M |
|
-- |
|
$17.51M |
|
$3.25M |
|
$6.09M |
|
$2.84M |
|
$7.95M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.47 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-14.67M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-13.62% |
|
-15.81% |
|
-7.21% |
|
-13.62% |
|
$4.67 |
|
$-1.33 |
|
$-1.33 |
|